One-Time gene injection aims to halt rare blindness
NCT ID NCT07653971
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial tests a single injection of a gene therapy called ZVS101e for people with Bietti crystalline dystrophy, a rare inherited eye disease that leads to progressive vision loss. The therapy uses a harmless virus to deliver a working copy of the CYP4V2 gene to cells in the eye. Participants receive one injection in the study eye and are followed for 4 weeks to check safety and early signs of effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ZVS101e (a gene therapy injection using a harmless virus to deliver a working copy of the CYP4V2 gene)
- What this could lead to
- If successful, this could provide a treatment option for people with Bietti crystalline dystrophy, potentially slowing vision loss or improving sight.
- What could go wrong
- This is an early-stage trial with a small number of participants, so results may not apply to everyone. Gene therapy carries risks like inflammation or retinal damage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BIETTI CRYSTALLINE CORNEORETINAL DYSTROPHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Boao Super Hospital
Qionghai, Hainan, China
-
Hainan Boao Ophthalmology Center, Zhongshan Ophthalmic Center, Sun Yat-sen University
Qionghai, Hainan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.